Clinical studies show that radiolabeled VIP analogues localize breast cancer, pancreatic cancer, intestinal adenocarcinomas, neuroendocrine tumors, and colorectal cancer using a combination of positron emission tomography (PET) and computed tomography (CT) scans110,113. The gene discussed is VIP; the disease is pancreatic neoplasm.